ZLAB - Zai Lab Limited Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 24.34 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 0.30 StockBond Score: -2.48 Company Description Operating primarily in Mainland China and Hong Kong Zai Lab Limited is a biopharmaceutical company focused on the discovery development and commercialization of innovative medical treatments Their therapeutic portfolio spans oncology autoimmune conditions infectious diseases and neurological disorders Currently available products in their portfolio include Zejula a oncedaily smallmolecule PARP 12 inhibitor Optune a medical device leveraging tumor treating fields NUZYRA an antimicrobial agent for specific acute bacterial skin and skin structure infections and communityacquired bacterial pneumonia and Qinlock indicated for gastrointestinal stromal tumors Beyond its commercial offerings Zai Lab boasts an extensive pipeline of investigational therapies These include Odronextamab for various Bcell lymphomas Repotrectinib a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKInaive and pretreated cancer patients Margetuximab for breast and gastroesophageal cancers Adagrasib for KRASG12Cmutated solid tumors like NSCLC colorectal and pancreatic cancers and Bemarituzumab for gastric and gastroesophageal junction cancers Further pipeline candidates encompass CLN081 for EGFR exon 20 insertion NSCLC Elzovantinib an orally available multitargeted kinase inhibitor Tebotelimab a tetravalent IgG4 monoclonal antibody Retifanlimab designed to block PD1 interactions with its ligands ZL2309 an orally active and selective CDC7 kinase inhibitor ZL1201 a humanized IgG4 monoclonal antibody Efgartigimod aimed at reducing pathogenic immunoglobulin G antibodies ZL1102 a human nanobody against interleukin17A KarXT for psychiatric and neurological conditions ZL2313 and ZL2314 both investigational EGFR inhibitors targeting specific mutations and Sulbactamdurlobactam intended for serious infections caused by Acinetobacter Established in 2013 Zai Lab Limited maintains its corporate headquarters in Shanghai China